{'fraction_non_alphanumeric': 0.01867816091954023, 'fraction_numerical': 0.004310344827586207, 'mean_word_length': 5.514018691588785, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reduction of blood group A antigen on erythrocytes in a patient with myelodysplastic syndrome harboring somatic mutations in RUNX1 and GATA2

Reduction of blood group ABO antigens on red blood cells (RBCs) is well known in patients with leukemias, and this reduction of ABO expression is strongly associated with DNA methylation of the ABO promoter. Previously, we reported a two‐nucleotide deletion in RUNX1 encoding an abnormally elongated protein lacking the trans‐activation domain in a patient with myelodysplastic syndrome (MDS) showing A‐antigen loss on RBCs. This prompted us to investigate the underlying mechanism responsible for A‐antigen reduction on RBCs in another patient with MDS.